UNSPSC 51384511: Ketoprofen

This classification denotes a nonsteroidal antiinflammatory drug with the molecular formula C16H14O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 90Y4QC304K, chemically known as propionic acid, 2-(3-benzoylphenyl)- but generally known as ketoprofen, which bears US NIH Compound Identifier 3825. European Medicines Agency schedules Ketoprofen in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08374MIG.

UNSPSC 51384511 Ketoprofen is a Commodity code that nominally covers a single nonsteroidal anti-inflammatory drug (NSAID), yet the recent state and local opportunities tagged under it reveal a much broader pharmaceutical and over-the-counter products market. State and local governments procure generic multi-source pharmaceuticals, naloxone, drug deactivation systems, and related health-supply products through this code, sourced via cooperative purchasing alliances, direct manufacturer relationships, and county health departments. Issuing bodies span state health agencies (Texas Health and Human Services Commission, Minnesota Department of Administration), regional cooperative purchasing organizations (Minnesota Multistate Cooperative Purchasing Alliance), and county health departments (Seminole County, Florida). The code reflects a mix of ongoing commodity contracts with multi-year terms and exploratory market-intelligence solicitations designed to reshape procurement strategy before formal RFP issuance.

Recent activity appears concentrated in the South and Upper Midwest. The Minnesota Multistate Cooperative Purchasing Alliance issued an RFP on January 20, 2026 (response deadline March 26, 2026) to establish multiple generic pharmaceutical and OTC product contracts across participating state and local facilities in Minnesota, Oregon, and other member jurisdictions, with wholesaler distribution through AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson. Seminole County, Florida issued an IFB (Solicitation IFB60459723LAS, response deadline July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually through quarterly deliveries to its Community Health Building in Sanford. The Texas Health and Human Services Commission posted a Request for Information on April 3, 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling intent to move beyond traditional pharmacy benefit manager and group purchasing organization arrangements. None of these opportunities explicitly name set-asides or disadvantaged-enterprise restrictions.